Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECTS OF BETAHISTINE DIHYDROCHLORIDE AS ADJUVANT TO ENALAPRIL THERAPY OF PATIENTS WITH CHRONIC HEART FAILURE CLASS II-II (NYHA) SUFFERING FROM GIDDINESS

https://doi.org/10.20996/1819-6446-2008-4-5-16-22

Full Text:

Abstract

Aim. To study adjuvant effect of betahistine dihydrochloride to ACE inhibitors in patients with chronic heart failure (CHF) class II-III suffering from giddiness.

Material and methods. 61 patients with CHF class II-III, ejection fraction ≤45% (Simpson) suffering from giddiness were involved into randomized open parallel study. Patients were randomized to Betahistine dihydrochloride plus basic CHF therapy or only basic therapy groups. Enalapril dose titration was performed in all patients. Quality of life and giddiness severity evaluation, electrocardiogram was performed initially and after treatment. Clinical examination results, drug therapy and adverse event were registered at each visit.

Results. The target ACE inhibitor dose (≥20 mg daily) was reached in 97 % of patients. It led to significant reduction of dyspnea, edemas, CHF class reduction and life quality increase. Significant differences between investigated groups were not found. Reduction of giddiness severity was shown in both groups. There was a trend to more prominent improvement of life quality (р=0,08) and more frequent achievement of target ACE inhibitor dose in patients treated with betahistine dihydrochloride.

Conclusion. The target ACE inhibitor dose can be achieved more than in 90% of patients with CHF class II-III without hypotension symptoms. Adjuvant usage of betahistine dihydrochloride is necessary in patients with CHF still suffering from giddiness after achievement of target ACE inhibitor dose.

About the Authors

S. Y. Martsevich
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia Moscow Medical Academy named after I.M. Setchenov, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Chair of Evidence Based Medicine


J. V. Lukina
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia Moscow Medical Academy named after I.M. Setchenov, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Chair of Evidence Based Medicine


V. V. Yakusevich
Yaroslavl State Medical Academy, ul. Revolucionnaya 5, Yaroslavl, 150000 Russia
Russian Federation
Chair of Clinical Pharmacology


D. A. Anichkov
Russian State Medical University, Leninsky prosp. 8, Moscow, 117049 Russia
Russian Federation
Chair of Faculty Therapy named after A.I.Nesterov


A. D. Deev
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


O. V. Lerman
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


S. N. Tolpygina
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


N. A. Dmitrieva
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


A. A. Serazhim
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


M. A. Maksimova
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


V. P. Voronina
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


E. V. Shilova
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


G. F. Andreeva
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


A. V. Zaharova
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Working group


I. V. Novikov
Russian State Medical University, Leninsky prosp. 8, Moscow, 117049 Russia
Russian Federation
Working group, Chair of Faculty Therapy named after A.I.Nesterov


А. А. Platonova
Russian State Medical University, Leninsky prosp. 8, Moscow, 117049 Russia
Russian Federation
Working group, Chair of Faculty Therapy named after A.I.Nesterov


Т. А. Kazakovtseva
Russian State Medical University, Leninsky prosp. 8, Moscow, 117049 Russia
Russian Federation
Working group, Chair of Faculty Therapy named after A.I.Nesterov


T. V. Babkova
Yaroslavl State Medical Academy, ul. Revolucionnaya 5, Yaroslavl, 150000 Russia
Russian Federation
Working group,Chair of Clinical Pharmacology


L. P. Volhonskaya
Yaroslavl State Medical Academy, ul. Revolucionnaya 5, Yaroslavl, 150000 Russia
Russian Federation
Working group,Chair of Clinical Pharmacology


References

1. Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная недостаточность 2006;8(2):1-35.

2. Агеев Ф.Т, Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная недостаточность. 2004; 5(1):4-7.

3. Swedberg K., Cleland J., Dargie H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26(11):1115-40.

4. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недоста- точность. Избранные лекции по кардиологии. М.: ГЭОТАР-Медиа; 2006.

5. Agustí A., Bonet S., Arnau J.M. et al. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials. Drug Saf 2003;26(12):895-908.

6. Терещенко С.Н., редактор. Некоторые нерешенные вопросы хронической сердечной недостаточности. М.: Миклош; 2007.

7. Siegrist J., Junge A. Conceptual and methodological problems in research on the quality of life in clinical medicine. Soc Sci Med 1989; 29(3):463-8.

8. Андреева Г.Ф., Горбунов В.М., Жигарева И.П. и соавт. Распространенность и наиболее частые причины возникновения головокружения у больных со стабильной артериальной гипертензией. Кардиоваскулярная терапия и профилактика 2004;(2):17-24.

9. Алексеева Н.С. Артериальная гипертензия и головокружение. Международные медицинские новости 2001;(3):1.

10. Андреева Г.Ф., Марцевич С.Ю., Горбунов В.М. и др. Оценка действия комбинации бетагистина дигидрохлорида с антигипертензивными препаратами на качество жизни больных стабильной артериальной гипертензией и головокружением. Кардиоваскулярная терапия и профилактика 2005; (3 ч. I):35-9.

11. Jáuregui-Renaud K., Hermosillo A.G., Gómez A. et al. Vestibular function interferes in cardiovascular reflexes [corrected]. Arch Med Res. 2003;34(3):200- 4. Erratum in: Arch Med Res. 2003;34(5):444.


For citation:


Martsevich S.Y., Lukina J.V., Yakusevich V.V., Anichkov D.A., Deev A.D., Lerman O.V., Tolpygina S.N., Dmitrieva N.A., Serazhim A.A., Maksimova M.A., Voronina V.P., Shilova E.V., Andreeva G.F., Zaharova A.V., Novikov I.V., Platonova А.А., Kazakovtseva Т.А., Babkova T.V., Volhonskaya L.P. EFFECTS OF BETAHISTINE DIHYDROCHLORIDE AS ADJUVANT TO ENALAPRIL THERAPY OF PATIENTS WITH CHRONIC HEART FAILURE CLASS II-II (NYHA) SUFFERING FROM GIDDINESS. Rational Pharmacotherapy in Cardiology. 2008;4(5):16-22. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-5-16-22

Views: 908


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)